Application 761298
- Type
- BLA
- Sponsor
- AMGEN INC
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761298 | Pavblu | aflibercept-ayyh | 351(k) Biosimilar | Rx | 2026-09-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | PAVBLU | AFLIBERCEPT-AYYH | INJECTABLE;INJECTION | 2 mg (0.05 mL of 40 mg/mL) | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| PAVBLU | AFLIBERCEPT-AYYH | Amgen, Inc | c61062f3-80ec-4a20-8c28-46e468592a06 | 2026-05-10 | Warnings, Adverse reactions | BLA761298 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.